At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 71 enrolled
Drug / intervention
dexamethasone implantdrug
Likely dose
dexamethasone implant 700 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
In Brief
A Phase 4 clinical trial evaluating dexamethasone implant for Macular Edema and Retinal Vein Occlusion. Completed, enrolled 71 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema, Retinal Vein Occlusion
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionSep 2014
Study CompletionMar 2015
TodayJul 2026
First PostedJul 19, 2013
Enrollment StartJul 16, 2013
Primary CompletionSep 24, 2014
Study CompletionMar 30, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.0 years ago
Interventions
dexamethasone implantdrug
OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.